Valion Bio Leadership Change
Lisa Wolf has voluntarily resigned from her positions as President, Chief Operating Officer, and Chief Financial Officer of Valion Bio, Inc. Her resignation is scheduled to become effective on December 11, 2026.
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Valion Bio, Inc. filings on SEC EDGAR ↗
Filing type
Alerts
Time
2 alerts with these filters
Lisa Wolf has voluntarily resigned from her positions as President, Chief Operating Officer, and Chief Financial Officer of Valion Bio, Inc. Her resignation is scheduled to become effective on December 11, 2026.
Valion Bio, Inc. terminated the employment of Melinda Lackey, General Counsel and Senior Vice President of Legal Affairs, effective October 30, 2026. Under a separation agreement, she will receive a lump-sum cash severance payment of $26,750 and temporary COBRA premium coverage.